Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Actve is on a mission to change the way people connect with their favourite fitness creators. The company aspires to help creators earn an income and build a subscription business. Actve asserts that it caters to a variety of creator needs allowing them to live-stream their workouts, offer guided programs to customers, or use Actve's software to manage their clients. The company aims to become a contender in the digital fitness market that is projected to be worth £21 billion by 2022. It aims to launch its platform in September 2021. Actve will use the investment to develop its platform, hire key staff, build its user base, and work towards becoming an industry champion for fitness creators.
days to go:
Expired
investment:
£165,627
FloatWind manufactures mass-produced floating offshore wind turbines. It seeks to disrupt the £20 billion offshore wind energy market. The company argues that conventional offshore wind farms, installed at sea, use expensive and slow installation methods that are also dangerous to the marine environment. It further stresses that the high cost of installation is often borne by the consumer. FloatWind asserts that its business model is different. The company claims to build its products on land and then floats its ready-to-float turbines out to sea. The company points out that this reduces environmental damage, substantially reduces costs, and makes offshore wind energy cheaper. FloatWind was selected for a 6-month UK Innovate Edge business mentoring programme and appeared for SetSquared Business Mentoring Seminar in May 2021. The company has 3,000+ followers on LinkedIn. FloatWind states it will use the investment for product development, expanding its team, IP protection, promoting marketing and PR, and boosting its manufacturing capabilities.
days to go:
Expired
investment:
£311,497
Charm is a peer-to-peer impact investment platform that allows a user to use his/her investments to drive positive change in the world while earning a financial return. Morgan Stanley estimates that 85% of people are interested in sustainable investing. Charm enables individuals to fund projects led by high-impact entrepreneurs selling clean energy solutions in developing economies. Users can view their investments on the company's transparent, personalised impact investment dashboard, as well as, earn social, environmental and financial bottom line returns for their contributions. The company secured a £496,000 grant funding to develop its platform, refine its offering & provide growth capital. It is in the process of becoming an appointed representative of a Financial Conduct Authority (FCA) authorised entity post this funding round. It will use the investment to expand its team, develop its platform, and raise brand awareness.
days to go:
Expired
investment:
£273,720
Docandu is an innovative digital health platform designed both for patients & doctors, making digital healthcare accessible from anywhere. Docandu aims to be a key tech health service provider, starting from Greece, improving the existing national and private health care services. The global digital health market is estimated to be worth $536 Billion by 2025. To date, they have developed two separate apps for doctors and patients. They have also received an angel investment of 100,000 Euros and sponsorship of $25,000 from Microsoft. The company has initiated early-stage relationships with a couple of Greek public and private health entities. With the proceeds, they will execute their go-to-market strategy and make global health ID a reality, by expanding its affiliate network of doctors, health providers and public health systems.
days to go:
Expired
investment:
£70,900
miiCARE is a MedTech specialising in AI applied to geriatrics (elderly care). Its key product miiCUBE offers cutting-edge home-based and customised healthcare, helping the elderly enjoy their independence while being comprehensively connected to their families, friends, and neighbours. The company aims to provide these benefits to one billion people by 2028, comprising older people, family members and carers. Till date, miiCARE has secured partnerships with the UK’s largest NHS trust, Ebbsfleet Garden City, O2, Bristol Careline and Microsoft, and won multiple social impacts and digital health awards during the last 12 months. Funds raised will be used mainly for fulfilling pre-orders and close interests for large contracts with corporates, marketing and logistics, product development, sales and salaries.
days to go:
Expired
investment:
£103,672
Peerport Limited (trading as MultiISA) is targeting the multi-million-pound market and claims to offer a holistic approach to Individual Savings Account (ISA) management. The company asserts that traditional ISA managers don’t give users enough flexibility with their investment choices. Current ISA rules restrict investors to only one ISA of each type per tax year. This impedes the investors’ ability to build a diversified IFISA portfolio. Peerport argues that its portal offers investors the freedom to operate multiple accounts like Innovative Finance ISA (IFISA), Cash ISA, and Stocks & Shares ISA under a single ISA management platform. The company will use the investment to finalise the build-out of its end to end platform, fund its office space, manage marketing costs, oversee staffing costs, pay regulatory fees and supervise working capital.
days to go:
Expired
investment:
£6,033
